GCG and metabolic dysfunction-associated steatotic liver disease: One major difference between the models of glucagon signalling deficiency and people with MASLD is that the former have improved glucose tolerance compared to controls, whereas people with MASLD have a high prevalence of pre-diabetes and type 2 diabetes (Cao et al. 2024).